Related Experiment Video

Updated: Jun 4, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

Helicobacter pylori therapy in children: a focus on proton pump inhibitors

Claudio Chiesa1, Caterina Anania, Lucia Pacifico

  • 1Institute of Molecular Medicine, National Research Council, Rome, Italy. claudio.chiesa@artov.inmm.cnr.it

Chemotherapy
|February 25, 2011
PubMed

Insights

Proton pump inhibitors (PPIs) are key in pediatric Helicobacter pylori eradication, but efficacy varies. This review examines PPIs

Area of Science:

  • Pediatric Gastroenterology
  • Pharmacology
  • Microbiology

Background:

  • Helicobacter pylori eradication in children remains challenging, with no universally effective and safe treatment regimen.
  • Individual variability in pediatric drug response is influenced by multifactorial determinants including genetics and development.
  • Proton pump inhibitors (PPIs) are integral components of triple therapy regimens for H. pylori eradication in children.

Purpose of the Study:

  • To comprehensively review proton pump inhibitors (PPIs) for H. pylori eradication in children from a pediatric perspective.
  • To discuss the clinical, pharmacologic, and microbiologic properties of PPIs in pediatric populations.
  • To explore host-related factors influencing PPI efficacy in pediatric H. pylori eradication.

Main Methods:

  • Systematic literature review focusing on pediatric studies of H. pylori eradication.
  • Analysis of clinical, pharmacologic, and microbiologic data related to PPI use in children.
  • Discussion of genetic, developmental, and host-related factors impacting PPI efficacy.

Main Results:

  • Commonly tested regimens include PPIs with clarithromycin and amoxicillin or nitroimidazoles.
  • PPIs play a crucial role in current pediatric H. pylori eradication strategies.
  • Factors such as genetics and development significantly influence PPI effectiveness in children.

Conclusions:

  • PPIs are essential but not always sufficient for successful H. pylori eradication in pediatric patients.
  • Understanding individual variability in drug response is critical for optimizing treatment.
  • Further research is needed to refine PPI-based therapies and address limitations in pediatric H. pylori management.

More Related Videos

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance06:40

Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance

Published on: July 28, 2023

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.